CirCode Biomed
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
CirCode Biomed is a clinical-stage biotechnology company pioneering the development of circular RNA (circRNA) therapeutics. Leveraging a proprietary circRNA technology platform, CirCode has built an integrated engine spanning AI-enabled sequence design and optimization, proprietary circularization system, and scalable manufacturing processes. This platform is designed to enable robust, durable protein expression with favorable safety and immunogenicity profiles, unlocking the therapeutic potential of circRNA across a broad range of serious and chronic diseases. Built on this technology foundation, CirCode is advancing pipeline led by HM2002 for ischemic heart disease, which has received IND approvals from both China’s NMPA and the U.S. FDA, as well as FDA Fast Track designation. The company is also developing innovative in vivo CAR therapy portfolio, to enable transient yet potent cell engineering directly within the body and address high-unmet-need indications.
Company HQ City:
Shanghai
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2018
Lead Product in Development:
HM2002 – a clinical-stage circRNA therapeutic for ischemic heart disease, enabling sustained in vivo expression of VEGF to promote therapeutic angiogenesis and improve myocardial perfusion
HM2003 – IIT stage circRNA therapeutic for lower limb ischemia, designed to drive localized and durable expression of pro-angiogenic factors to restore blood flow and tissue function
CC2402 – an in vivo CAR-T program based on circRNA delivery, enabling transient and controllable generation of CAR-T cells in the body for autoimmune diseases
HM3008 – an in vivo CAR-M program leveraging circRNA to engineer macrophages in situ, delivered via intraperitoneal administration for the treatment of malignant ascites in solid tumors, aiming to enhance tumor cell phagocytosis and remodel the immunosuppressive microenvironment
CEO
Dr. Chenxiang Tang
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
HM2002: ongoing phase 1 Nov. 2026, CCS phase 1 Jun. 2026
HM2003: Oct. 2026
CC2402: Aug 2026
HM3008: Jun 2026
What is your next catalyst (value inflection) update?
HM2002: initial clinical data readout from ongoing phase I, initiate chronic coronary syndrome indication phase I study
HM2003: initial clinical data readout from ongoing IIT study
CC2402: data readout from NHP pre-clinical study, initiate of IIT study
HM3008: initiate of IIT study
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}